Diagnostic moléculaire des hémopathies malignes 79
28. Böttcher S, Ritgen M, Fischer K, et al. (2012) Minimal residual disease quantification is
an independent predictor of progression-free and overall survival in chronic lymphocytic
leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol.
30: 980-8
29. Puente XS, Pinyol M, Quesada V, Conde L (2011) Whole-genome sequencing identifies
recurrent mutations in chronic lymphocytic leukaemia. Nature. 475: 101-5
30. Rossi D, Rasi S, Spina V, et al. (2013). Integrated mutational and cytogenetic analysis
identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood [epub ahead
of print]
31. Treon SP, Cao Y, Xu L, et al. (2014) Somatic mutations in MYD88 and CXCR4
are determinants of clinical presentation and overall survival in Waldenstrom
macroglobulinemia. Blood 123: 2791-6
32. Schultz KR, Pullen DJ, Sather HN, et al. (2007) Risk- and response-based classification of
childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic
markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).
Blood. 109: 926-35
33. Mullighan GG (2012) The molecular genetic makeup of acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ program 389-396
34. van der Veer A, Waanders E, Pieters R, et al. (2013) Independent prognostic value of
BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in
children with B-cell precursor ALL. Blood 122: 2622-9
35. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. (2013). Toward a NOTCH1/
FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute
Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia
Study. JCO: 4333-4342
36. Beldjord K, Chevret S, Asnafi V, et al. (2014) Oncogenetics and minimal residual disease
are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Blood [epub ahead of print]
37. Grimwade D, Walker H, Harrison G, et al. (2001).The predictive value of hierarchical
cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of
1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Blood 98: 1312-20
38. Döhner H, Estey EH, Amadori S, et al. (2010) Diagnosis and management of acute
myeloid leukemia in adults: recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood 115: 453-74
39. Liersch R, Müller-Tidow C, Berdel WE, Krug U (2014) Prognostic factors for acute
myeloid leukaemia in adults-biological significance and clinical use. Br J Haematol. 165:
17-38
40. Schlenk RF, Döhner H. (2013) Genomic applications in the clinic: use in treatment
paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program:324-30
41. Jourdan E, Noissel N, Chevert S, et al. (2013) Prospective evaluation of gene mutations
and minimal residual disease (MRD) in patients with core binding factor acute myeloid
leukemia (CBF-ALML). Blood, 121: 2213-23
42. Lengfelder E, Saussele S, Weisser A, et al. (2005) Treatment concepts of acute promyelocytic
leukemia. Crit Rev Oncol Hematol. 56: 261-74
43. Buccisano F, Maurillo L, Del Principe MI, et al. (2012) Prognostic and therapeutic
implications of minimal residual disease detection in acute myeloid leukemia. Blood 119:
332-41
44. Patel J, Mithat G, Figueroa M, et al. (2012) Prognostic relevance of integrated genetic
profiling in acute myeloid leukemia.N Engl J Med 366: 1079-1089
45. Grossmann V, Schnittger S, Kohlmann A, et al. (2012) A novel hierarchical prognostic
model of AML solely based on molecular mutations. Blood 120: 2963-72
28. Böttcher S, Ritgen M, Fischer K, et al. (2012) Minimal residual disease quantification is
an independent predictor of progression-free and overall survival in chronic lymphocytic
leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol.
30: 980-8
29. Puente XS, Pinyol M, Quesada V, Conde L (2011) Whole-genome sequencing identifies
recurrent mutations in chronic lymphocytic leukaemia. Nature. 475: 101-5
30. Rossi D, Rasi S, Spina V, et al. (2013). Integrated mutational and cytogenetic analysis
identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood [epub ahead
of print]
31. Treon SP, Cao Y, Xu L, et al. (2014) Somatic mutations in MYD88 and CXCR4
are determinants of clinical presentation and overall survival in Waldenstrom
macroglobulinemia. Blood 123: 2791-6
32. Schultz KR, Pullen DJ, Sather HN, et al. (2007) Risk- and response-based classification of
childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic
markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).
Blood. 109: 926-35
33. Mullighan GG (2012) The molecular genetic makeup of acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ program 389-396
34. van der Veer A, Waanders E, Pieters R, et al. (2013) Independent prognostic value of
BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in
children with B-cell precursor ALL. Blood 122: 2622-9
35. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. (2013). Toward a NOTCH1/
FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute
Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia
Study. JCO: 4333-4342
36. Beldjord K, Chevret S, Asnafi V, et al. (2014) Oncogenetics and minimal residual disease
are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Blood [epub ahead of print]
37. Grimwade D, Walker H, Harrison G, et al. (2001).The predictive value of hierarchical
cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of
1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Blood 98: 1312-20
38. Döhner H, Estey EH, Amadori S, et al. (2010) Diagnosis and management of acute
myeloid leukemia in adults: recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood 115: 453-74
39. Liersch R, Müller-Tidow C, Berdel WE, Krug U (2014) Prognostic factors for acute
myeloid leukaemia in adults-biological significance and clinical use. Br J Haematol. 165:
17-38
40. Schlenk RF, Döhner H. (2013) Genomic applications in the clinic: use in treatment
paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program:324-30
41. Jourdan E, Noissel N, Chevert S, et al. (2013) Prospective evaluation of gene mutations
and minimal residual disease (MRD) in patients with core binding factor acute myeloid
leukemia (CBF-ALML). Blood, 121: 2213-23
42. Lengfelder E, Saussele S, Weisser A, et al. (2005) Treatment concepts of acute promyelocytic
leukemia. Crit Rev Oncol Hematol. 56: 261-74
43. Buccisano F, Maurillo L, Del Principe MI, et al. (2012) Prognostic and therapeutic
implications of minimal residual disease detection in acute myeloid leukemia. Blood 119:
332-41
44. Patel J, Mithat G, Figueroa M, et al. (2012) Prognostic relevance of integrated genetic
profiling in acute myeloid leukemia.N Engl J Med 366: 1079-1089
45. Grossmann V, Schnittger S, Kohlmann A, et al. (2012) A novel hierarchical prognostic
model of AML solely based on molecular mutations. Blood 120: 2963-72